Cancer remains a leading cause of death worldwide due to the lack of safer and more
effective therapies. Cancer vaccines developed from neoantigens are an emerging strategy …

Carbohydrates are abundantly expressed on the surface of both eukaryotic and prokaryotic
cells, often as post translational modifications of proteins. Glycoproteins are recognized by …

Tumor‐associated carbohydrate antigens (TACAs) are key components of cancer vaccines.
A variety of vaccines based on native TACAs such as α‐Tn have shown immunogenicity and …

Herein, we have summarized the vast array of synthetic processes that have been
developed for the synthesis of C-glycopyranosyl aldehydes and diverse C-glycoconjugates …

The Tn antigen (GalNAc-α-1-O-Thr/Ser) is a well-known tumor-associated carbohydrate
determinant. The use of glycopeptides that incorporate this structure has become a …

Fully synthetic tumor-associated carbohydrate antigen (TACA)-based vaccines are a
promising strategy to treat cancer. To overcome the intrinsic low immunogenicity of TACAs …

MUC1 glycopeptides are attractive antigens for anti-cancer vaccine development. One
potential drawback in using the native MUC1 glycopeptide for vaccine design is the …

A tripartite cancer vaccine candidate, containing a quaternary amino acid (α-methylserine) in
the most immunogenic domain of MUC1, has been synthesized and examined for antigenic …

Stereoselective sulfa-Michael addition of appropriately protected thiocarbohydrates to chiral
dehydroalanines has been developed as a key step in the synthesis of biologically important …

It is well known that tumor cells express some aberrant glycans, termed tumor-associated
carbohydrate antigens (TACAs). TACAs are good targets for the development of …